Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies
Authors, Journal, Affiliations, Type, DOI
- Authors: Michael J. Ackerman (Chair), Douglas P. Zipes, Richard J. Kovacs, Barry J. Maron
- Journal: Circulation, 1 December 2015;132:e326–e329; co-published in the Journal of the American College of Cardiology
- Affiliations: AHA Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and the American College of Cardiology
- Type: Scientific statement — Task Force 10 of the AHA/ACC "Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities" series (14 task forces)
- DOI: https://doi.org/10.1161/CIR.0000000000000246
Overview
The Task Force 10 statement sets the 2015 AHA/ACC position on competitive sports participation for athletes with the six cardiac channelopathies — long-QT syndrome, catecholaminergic polymorphic ventricular tachycardia, Brugada syndrome, early repolarization syndrome, short-QT syndrome and idiopathic ventricular fibrillation. It replaces the post-2005 recommendation that restricted athletes with any channelopathy from all competitive sport with a phenotype-graded scheme in which only previously symptomatic athletes (Class I restriction) and CPVT with exercise-induced ventricular ectopy (Class III) are actually excluded; concealed genotype-positive athletes are cleared at Class IIa and manifest disease is cleared at Class IIb. The shift rests on four developments the writing group lists explicitly, including the first observational data from athletes with LQTS who remained competitive against advice (>650 athlete-years with a single appropriate shock), and it is candid that every recommendation is Level of Evidence C. The statement remains the historical reference point against which the 2025 AHA/ACC shared-decision-making framework is measured.
Keywords
Athletes · Brugada syndrome · Cardiovascular abnormalities · Channelopathies · Heart rhythm disorders · Long QT syndrome · Competitive sports · Disqualification · Shared decision-making
Key Takeaways
Scope and Definitions
- The six channelopathies covered: LQTS, CPVT, Brugada syndrome (BrS), early repolarization syndrome (ERS), short-QT syndrome (SQTS), and "potentially" idiopathic ventricular fibrillation (IVF).
- Previously symptomatic athlete — at least one channelopathy-triggered or suspected syncope, seizure, or aborted/resuscitated cardiac arrest.
- Concealed channelopathy — an asymptomatic athlete with a positive genetic test and no ECG evidence at rest: QTc <460 ms for LQTS; no spontaneous type 1 Brugada pattern in the right precordial leads; no horizontal or downsloping early repolarization pattern in inferolateral leads; QTc >380 ms for SQTS; and, for CPVT, no exercise-induced premature ventricular complexes in bigeminy, couplets or worse. Synonymous with genotype-positive/phenotype-negative.
- Disease-specific treatment means drug therapy, denervation (left cardiac sympathetic denervation for LQTS and CPVT), device therapy (an ICD rather than a pacemaker when a device is indicated), or a combination.
- An ICD is not implanted to keep an athlete in sport. Treatment is chosen on phenotype severity, and the athlete's status must not influence the device decision.
The 2005 Position and the Four Developments Since
- Since 2005 the guideline position had been restriction from virtually all competitive sport for any channelopathy, regardless of subtype — even though exercise had been established as a proarrhythmic trigger only for CPVT and LQTS (particularly LQT1).
- Development 1 — genetic testing became routine, with the 2011 HRS/EHRA consensus statement as the first clinical-use guideline.
- Development 2 — no sentinel event has been reported during sport in a US athlete with a concealed channelopathy, despite wider genotype-positive ascertainment. The writing group reads this as no observational support for the European position of disqualifying on a positive genetic test alone.
- Development 3 — the first outcome data from athletes who stayed competitive. In a single-centre series of 130 athletes with LQTS, one athlete with LQT1 had two exercise-triggered events terminated by appropriate ICD therapy (baseball and soccer) across more than 650 athlete-years; every athlete had undergone a 2–3-day specialist evaluation. The experience was reproduced in genotype-positive children at a second centre.
- Development 4 — the North American ICD Sports Registry, then >340 athletes, reported zero deaths at a mean 31 months with no excess device damage or inappropriate shocks. LQTS was the most common underlying disease, followed by hypertrophic and arrhythmogenic right ventricular cardiomyopathy.
- No equivalent data exist for CPVT. Because CPVT is the channelopathy most vulnerable to exercise, breakthrough events on beta-blockade are more likely than in LQTS and the potential for arrhythmic/ICD storm is greatest — the basis for the one Class III recommendation in the document.
Precautionary Measures
Applies to every participating athlete with a channelopathy, concealed or manifest:
- Avoid QT-prolonging drugs in LQTS (crediblemeds.org).
- Avoid drugs that aggravate BrS (brugadadrugs.org).
- Maintain electrolytes and hydration; avoid dehydration.
- Avoid or treat hyperthermia from febrile illness or training-related heat exhaustion/heat stroke in LQTS and BrS.
- Acquire a personal automated external defibrillator as part of the athlete's own safety equipment.
- Establish an emergency action plan with school or team officials.
Recommendations
| # | Recommendation | Class | LOE |
|---|---|---|---|
| 1 | Comprehensive evaluation by a heart rhythm specialist or genetic cardiologist with sufficient channelopathy expertise | I | C |
| 2 | Symptomatic athletes with any suspected or diagnosed channelopathy restricted from all competitive sport until evaluation is complete, the athlete and family are informed, treatment is implemented, and the athlete has been asymptomatic on therapy for 3 months | I | C |
| 3 | Asymptomatic genotype-positive/phenotype-negative LQTS, CPVT, BrS, ERS, IVF or SQTS: participation in all competitive sport with precautionary measures | IIa | C |
| 4 | Previously symptomatic or ECG-evident BrS, ERS or SQTS: participation may be considered with precautionary measures and disease-specific treatment, asymptomatic on treatment ≥3 months | IIb | C |
| 5 | Symptomatic or ECG-manifest LQTS (QTc >470 ms in males, >480 ms in females): participation may be considered after treatment and precautionary measures, asymptomatic on treatment ≥3 months — except competitive swimming in a previously symptomatic LQT1 host | IIb | C |
| 6 | Previously symptomatic CPVT, or asymptomatic CPVT with exercise-induced bigeminy, couplets or NSVT: competitive sport not recommended except class IA sports (low static and low dynamic demand); exceptions only after CPVT specialist consultation | III | C |
- Recommendation 3 covers CPVT only in its concealed form — genotype-positive with a negative exercise stress test. Once ectopy appears on stress testing, recommendation 6 applies.
- A 3-month temporary restriction is prudent after any cardiac event in a suspected or known channelopathy, to allow evaluation, counselling and treatment modification.
- Diagnostic uncertainty is the stated rationale for specialist referral. In one series, 40% of patients given a LQTS diagnosis by a heart rhythm specialist were reclassified as normal at a LQTS specialty centre.
- All recommendations are Level of Evidence C, and the document says so explicitly.
Epidemiology Given
- Approximately 1 in 1,000 people are affected by a cardiac channelopathy overall.
- LQTS is the most common, at an estimated 1 in 2,000.
Limitations of the document
- Level of Evidence C throughout — every recommendation is expert consensus, with no randomised or even prospective comparative data on athlete outcomes.
- The LQTS outcome data are from one centre with a 2–3-day specialist evaluation; the authors note this as an important caveat and the model may not transfer to routine practice.
- No CPVT athlete data exist at all — the Class III recommendation is an inference from mechanism and from the known exercise dependence of the phenotype.
- Registry follow-up is short (mean 31 months) and enrolment is self-selected.
- Sports classification uses the older static/dynamic scheme, which the 2025 AHA/ACC statement replaces with an endurance–strength continuum.
- Predates the 2017 AHA/ACC/HRS VA/SCD guideline, the 2022 ESC VA/SCD guideline and the 2025 AHA/ACC competitive sports statement, all of which revise the participation framework it establishes.
- Covers only the channelopathies; structural disease, arrhythmias and conduction defects sit in the companion Task Force reports.
Key Concepts Mentioned
- concepts/Channelopathies — the six syndromes as one class
- concepts/Sports-Cardiology-SDM — the framework that supersedes this statement
- concepts/Genetic-Testing-in-Arrhythmias — genetic testing as the basis for concealed-disease ascertainment
- concepts/Left-Cardiac-Sympathetic-Denervation — named as a disease-specific treatment option
- concepts/Sudden-Cardiac-Death — the outcome being prevented
- concepts/Torsades-de-Pointes — the arrhythmia mechanism named for LQTS
- concepts/LQTS-Pregnancy-Management — the analogous phenotype-graded risk framework in pregnancy
Key Entities Mentioned
- entities/Long-QT-Syndrome — Class IIa concealed, Class IIb manifest
- entities/CPVT — Class III with exercise-induced ectopy; Class IIa when concealed
- entities/Brugada-Syndrome — Class IIa concealed, Class IIb manifest
- entities/Early-Repolarization-Syndrome — Class IIa concealed, Class IIb manifest
- entities/Short-QT-Syndrome — Class IIa concealed, Class IIb manifest
- entities/Idiopathic-Ventricular-Fibrillation — Class IIa when concealed
- entities/ICD — device therapy; not to be implanted solely to enable sport
Wiki Pages Updated
- wiki/sources/competitive-athletes-channelopathies-aha-2015.md (created)
- wiki/sourceindex.md (updated)
- wiki/wikiindex.md (checked — no new concept or entity rows)
- wiki/concepts/Sports-Cardiology-SDM.md (updated — 2015 baseline and contradictions)
- wiki/concepts/Channelopathies.md (updated — sports participation position)
- wiki/entities/Long-QT-Syndrome.md (updated — competitive sports)
- wiki/entities/CPVT.md (updated — sports and exercise)
- wiki/entities/Brugada-Syndrome.md (updated — conservative management)
- wiki/entities/Short-QT-Syndrome.md (updated — management)
- wiki/entities/Early-Repolarization-Syndrome.md (updated — key facts)
- wiki/entities/Idiopathic-Ventricular-Fibrillation.md (updated — key facts)